Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
82-Rb PET for Grading Kidney Carcinoma
NCT07346404Phase 2Not yet recruiting
- Sponsor
- Assistance publique - Hôpitaux de Paris
- Start
- Jan 2026
- Primary completion
- Jan 2028
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of rubidium-82 chloride in renal cell carcinoma (RCC), sponsored by Assistance publique - Hôpitaux de Paris. Planned start Jan 2026; status: not yet recruiting.
02
Drugs
rubidium-82 chloride
03
Conditions
renal cell carcinoma (RCC)
Beyond the preview
Go deeper on NCT07346404.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07346404.